"An Original Research Article for Evaluation of Changes in Tumor Size After Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Ductal Adenocarcinoma"

Pancreatic cancers may pose a formidable challenge to treating physicians with their relatively poorer prognoses despite multimodality management. Evaluation of resectability is critical for pancreatic cancers since the outcome is typically better for patients undergoing surgical resection as part of management. However, some tumors are classified as borderline resectable. Particularly for this group, utilization of neoadjuvant systemic therapy may have a role in multimodality management.